DR5在TRAIL诱导Jurkat细胞凋亡中的作用

目的：研究DR5在介导TRAIL凋亡信号中的作用。方法：用含人DR5细胞外全长结构域重组DR5免疫BALB／C小鼠，制备抗DR5单克隆抗体；流式细胞仪检测Jurkat细胞表面DR5表达水平；采用TRAIL凋亡检测试剂盒，检测Jurkat细胞凋亡率及抗DR5单克隆抗体对TRAIL诱导细胞凋亡的阻断率。结果：DR5在Jurkat细胞表面的表达率为94．83％，TRAIL和抗TRAIL单克隆抗体能够诱导Jurkat细胞凋亡，呈现明显的剂量相关性，TRAIL浓度在50-100ng/ml时，杀伤率达90％以上。预先用抗DR5单克隆抗体与Jurkat细胞作用后，TRAIL对Jurkat细胞的杀伤功能几乎完全被mAb所阻断，其平均阻断率达90．49％。结论：DR5在TRAIL诱导Jurkat细胞凋亡中起着十分关键的作用。     

TRAIL对多种肿瘤细胞的杀伤作用

目的： 研究肿瘤坏死因子相关凋亡诱导配体（TRAIL）作用下多种肿瘤细胞的生长抑制效应及凋亡诱导情况。方法： 利用大肠杆菌基因工程菌表达非融合rhsTRAIL，进行目的蛋白的分离纯化，得到rhsTRAIL样品，纯度为97%。通过倒置显微镜下观察、MTT法、流式细胞仪法检测其对细胞的生长抑制和诱导凋亡情况。结果： 一定浓度的TRAIL 可有效抑制LS174-T细胞、MCF-7细胞、GLC细胞、7402细胞、Jurkut T细胞生长，其生长抑制率具剂量依赖性，且各细胞对TRAIL敏感性不同，其中Jurkat T细胞最为敏感。用2 mg/L TRAIL作用Jurkat T细胞0-72 h，6 h后细胞即发生明显凋亡，其细胞凋亡率具时间依赖性。结论： 所制备的TRAIL可抑制多种肿瘤细胞生长，并诱导Jurkat T细胞凋亡。     

特异性ASODN抑制Fas表达降低FasL介导细胞凋亡的研究

为了研究特异性Fas反义寡核苷酸(ASODN)对T细胞Fas表达及肝癌细胞诱导其凋亡的抑制作用,用脂质体介导法将Fas ASODN导入Jurkat T细胞,并通过用流式细胞术、RT-PCR及与肝癌细胞共培养方法研究Fas ASODN对T细胞Fas表达、Fas mRNA水平及凋亡的影响。结果显示:①Hep G2.2.15细胞表达有功能的FasL,可诱导Jurkat细胞凋亡;②Jurkat细胞转染Fas ASODN后,Fas mRNA降低;细胞表面Fas表达下降;与Hep G2.2.15细胞共培养后的凋亡率下降。表明Fas ASODN转染可以部分逆转肝癌细胞对T细胞的凋亡诱导作用。     

ICA、PJA逆转人高转移肺癌细胞Fas/FasL途径免疫逃逸机制的研究

目的：研究ICA、PJA对人高转移肺癌细胞PG细胞免疫逃逸的逆转作用。方法：MTT法检测ICA、PJh对PG细胞增殖的影响以及对CD3AK杀伤敏感性的影响。流式细胞仪检测细胞表面分子Fas、FasL表达水平和细胞凋亡。应用PG细胞与Jurkat T细胞其培养的方法体外研究FasL诱导T淋巴细胞凋亡的作用。结果：PG细胞高表达FasL，低表达Fas，对CD3AK细胞杀伤敏感性较低，并在与Jurkat T细胞共培养中诱导高表达Fas的Jurkat T细胞凋亡。：ICA、PJA对PG细胞有明显的增殖抑制作用。ICA可明显提高PG细胞Fas的表达率。ICA、PJA可明显降低PG细胞FasL的表达率。ICA、PJA可使PG细胞与Jurkat T细胞共培养中，降低Jurkat T细胞的凋亡率。ICA、PJA可提高CD3AK细胞对PG细胞的杀伤活性。结论：ICA、PJA可逆转人高转移肺癌细胞PG通过Fas／FasL途径逃避机体免疫活性细胞的攻击。     

重组人可溶性TRAIL的制备及其联合硼替佐米诱导肿瘤细胞的凋亡作用

目的:构建重组人肿瘤坏死因子相关的凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)原核表达质粒p ET-28a(+)-TRAIL114-281,优化蛋白表达和纯化条件,制备重组人可溶性TRAIL并鉴定其活性。方法:使用CCK-8初步验证TRAIL是否具有抑制肿瘤细胞生长的生物活性;将制备的TRAIL单独或联合50 nmol/L硼替佐米应用于H460细胞(对TRAIL敏感)和K562细胞(对TRAIL抵抗)24 h,流式细胞术检测细胞凋亡率,比色法检测caspase-8、-9、-3的活化程度,Western blot分析细胞中Bax、Bcl-2和c FLIP蛋白的表达。流式细胞术检测硼替佐米处理H460细胞和K562细胞24 h后DR4和DR5的表达量变化。结果:制备了具有生物学活性且性质稳定的重组人可溶性TRAIL,且成功诱导H460和K562细胞凋亡。不同浓度TRAIL处理H460细胞后其凋亡率随着TRAIL浓度升高而显著升高(P0.05),但K562细胞凋亡率并未随着TRAIL浓度明显升高。联合用药组的H460和K562细胞凋亡率均显著高于单独用药组(P0.05),凋亡过程中caspase-8、-9、-3均被活化,药物处理组的Bcl-2和c FLIP表达量均比对照组下降,尤其联合用药组表达量下降最为显著(P0.05),而Bax表达量无明显变化。硼替佐米处理H460和K562细胞后DR4和DR5表达量均上调(P0.05)。结论:硼替佐米能协同TRAIL启动内源性凋亡途径诱导H460和K562细胞凋亡,其可能机制是通过上调死亡受体DR4和DR5的表达量、下调抗凋亡蛋白Bcl-2和c FLIP的表达量来实现的。     

IL-33及其受体ST2L在银屑病患者外周血T细胞及皮损组织中的表达北大核心CSCD

目的：研究IL-33及其受体ST2L在银屑病患者外周血T细胞和皮损组织中的表达。方法：采用免疫组织化学法检测寻常型银屑病（PV组）、脓疱型银屑病（PP组）和色素痣切除者[为对照组（CON组）]皮损中IL-33、ST2L的表达和分布。分别采用免疫印迹法和RT-PCR法检测经IL-17A诱导后Jurkat T细胞、HaCat角质形成细胞中IL-33及IL-33 mRNA的表达情况；用同样的方法检测经IL-33诱导后Jurkat T细胞、PV组T细胞、PP组T细胞、CON组T细胞中ST2L及ST2L mRNA表达情况。结果：PV组和PP组患者的皮损中，观察到IL-33及其受体ST2L蛋白在表皮和真皮细胞中均有不同密度的阳性染色。CON组T细胞中表达微量IL-33蛋白，但在银屑病组中，包括PV组和PP组中T细胞有IL-33蛋白明显表达，PP组表达量大于PV组，差异有统计学意义（P<0.05）;IL-33诱导Jurkat T细胞、PV组和PP组患者T细胞表达一定量ST2L蛋白和mRNA，呈剂量依赖性；PV组和PP组中ST2L蛋白表达高于在同一浓度CON组IL-33诱导产生的ST2L水平，差异具有统计学意义（P<0.05）;IL-17A诱导Jurkat T细胞产生IL-33蛋白和mRNA呈一定量效和时效关系；IL-17A诱导HaCat角质形成细胞表达IL-33蛋白和mRNA，呈剂量依赖性，IL-33蛋白主要在HaCat角质形成细胞的细胞核中表达，部分胞质有一定表达，且IL-17A高浓度刺激后，其表达量明显增加。结论：银屑病患者的外周血T细胞和皮损中IL-33及其受体ST2L表达水平明显升高，表明IL-33在银屑病的发生发展中可能发挥重要作用。     

可溶性人TRAIL分子对Jurkat细胞的杀伤作用

目的　研究可溶性人TRAIL蛋白 (sTRAIL)对Jurkat细胞的生长抑制效应及凋亡诱导作用。方法　通过RT PCR扩增人TRAIL分子胞外区 4 1～ 2 81的密码子 ,利用大肠杆菌DH5α表达该可溶性片段 ,经纯化和复性后 ,诱导Jurkat细胞 ,通过显微镜、台盼蓝排斥试验、MTT法、流式细胞仪和DNA断裂实验检测细胞增殖和细胞凋亡。结果　sTRAIL蛋白纯度达 90 %以上。用 0 .5～ 10 .0 μg/ml的蛋白诱导Jurkat细胞 12h以上细胞的生长和增殖即被显著抑制 ,并且观察到凋亡峰及DNA的片段化等凋亡的特征性变化 ,细胞的生长抑制率与凋亡率也呈剂量依赖和时间依赖关系。结论　利用大肠杆菌制备的sTRAIL41 2 81蛋白对Jurkat细胞具有明显的增殖抑制效应和凋亡诱导作用。     

CpG-ODN下调HeLa细胞功能性Fas配体的表达

为观察CpG-ODN对宫颈癌细胞系HeLa细胞Fas配体(FasL)表达水平的影响,探讨其对由HeLa细胞Fas-FasL途径诱导的淋巴细胞凋亡作用。采用实时荧光RT-PCR方法检测HeLa细胞、正常宫颈上皮细胞中FasL和Jurkat T淋巴细胞中Fas的表达水平,应用HeLa细胞与Jurkat细胞共培养的方法体外研究HeLa细胞FasL诱导T淋巴细胞凋亡作用。结果显示:①HeLa细胞、正常宫颈上皮细胞中FasL表达阳性,其表达水平分别是(0.99±0.05)、(0.68±0.03),差别具有统计学意义(P=0.0007);Jurkat细胞Fas表达呈阳性;②HeLa细胞与Jurkat细胞共培养后Jurkat细胞的凋亡率为(38.23%±4.98%),应用抗体NOK-2中和HeLa细胞的FasL后,Jurkat细胞凋亡率减少为(3.54%±1.61%),两者相比,差别有显著性意义(P=0.0001);③HeLa细胞用CpG-ODN处理前后FasL的表达水平分别是(0.99±0.05)、(0.79±0.04),差别有统计学意义(P=0.005);CpG-ODN预处理的HeLa细胞与Jurkat细胞共培养后Jurkat细胞凋亡率为(6.41%±2.81%),而没有用CpG-ODN预处理的HeLa细胞与Jurkat细胞共培养Jurkat细胞凋亡率为(29.23±6.85)%,二者的差别有统计学意义(t=13.39,P=0.006)。HeLa细胞可能通过表达FasL主动诱导T淋巴细胞凋亡从而在肿瘤的免疫逃逸中发挥作用,CpG-ODN可通过下调FasL的表达而减少肿瘤细胞主动诱导的T淋巴细胞凋亡。     

人可溶性TRAIL基因的克隆及表达

为了利用大肠杆菌表达人可溶性肿瘤坏死因子相关性凋亡诱导配体 (TRAIL )蛋白 ,应用RT PCR技术从激活的人外周血淋巴细胞总RNA中扩增人可溶性TRAIL蛋白cDNA ,克隆入PCR2 1 载体 ,测序验证后用基因重组法分别构建了人可溶性TRAIL蛋白的真核与原核表达质粒载体。将重组质粒分别转入COS 7和大肠杆菌M1 5中表达。用流式细胞仪检测人可溶性TRAIL蛋白在COS 7细胞中的瞬时表达 ,用SDS PAGE电泳和Westernblot鉴定大肠杆菌中的表达产物。所表达融合蛋白为人可溶性TRAIL蛋白分子 ,相对分子质量为 2 1 0 0 0 ,表达量约为 2mg/ml。所表达的人可溶性TRAIL蛋白具有诱导HL 60细胞凋亡的作用。上述结果提示大肠杆菌可良好表达具有生物活性的人可溶性TRAIL蛋白 ,为深入研究TRAIL分子在肿瘤与自身免疫性疾病中的可能应用提供了材料。     

重组人可溶性TRAIL分子诱导白血病细胞株凋亡的研究

比较重组人可溶性TRAIL(rhsTRAIL)诱导Jurkat细胞株、K562细胞株以及HL-60细胞株凋亡之间的差异,探讨这些差异与细胞表面TRAIL受体(DR4、DR5、DcR1和DcR2)表达量的关系。不同浓度的rhsTRAIL分别处理Jurkat细胞、K562细胞和HL-60细胞12 h、24 h和48 h后,用流式细胞仪检测经碘化丙啶(PI)染色后的细胞凋亡情况;用RT-PCR方法检测细胞表面受体DR4、DR5、DcR1、DcR2的表达。培养12 h、24 h、48 h后,不同浓度rhsTRAIL诱导Jurkat细胞株的凋亡率均明显高于对照组,且具有剂量依赖性和时间依赖性;但K562细胞株和HL-60细胞株未见明显的凋亡发生。RT-PCR结果显示,培养12 h、24 h、48 h后,Jurkat细胞株表面DR4的表达随时间的延长和rhsTRAIL浓度的升高而升高,而DR5、DcR1和DcR2的表达未检出;K562和HL-60细胞株表面DR4的表达没有明显变化,而且DR5、DcR1和DcR2的表达也未检出。rhsTRAIL诱导Jurkat细胞株的凋亡具有剂量依赖性和时间依赖性,且与其细胞表面DR4的表达呈正相关;在一定的浓度条件下,rhsTRAIL未能诱导K 562和HL-60细胞株发生明显凋亡,且其细胞表面DR4的表达也未见明显变化。这些结果提示,应用TRAIL治疗不同种类白血病时,应注意它的使用剂量和适应范围。     

白花丹醌增强TRAIL诱导Kasumi-1细胞凋亡及其机制

目的: 观察白花丹醌、rsTRAIL单独及其联合体外诱导Kasumi-1细胞凋亡的作用,探讨其作用机制。方法: 采用WST-8 (CCK-8)比色法测定rsTRAIL、白花丹醌单独和联合应用对Kasumi-1细胞的生长抑制率;用流式细胞术、TUNEL法观察并且检测凋亡率;实时定量PCR检测白花丹醌作用后DR4和DR5 mRNA水平变化;Western blotting法检测单独应用及联合应用后DR5、caspase-3、caspase-8、caspase-9、Bid、Bax及c-FLIP的变化。结果: (1)白花丹醌和rsTRAIL单独应用均可抑制Kasumi-1细胞的生长,联合应用可增加对Kasumi-1细胞的生长抑制率且呈时间和剂量依赖性(P<0.05)。(2)rsTRAIL(100 μg/L)和白花丹醌(2 μmol/L)单用及其联合使用诱导Kasumi-1细胞Annexin V阳性细胞百分率分别为(27.7±2.9)%、(25.6±3.1)%和(52.1±3.3)%。(3)TUNEL法检测发现联合应用组较单用组凋亡细胞显著增多。(4)实时定量PCR检测发现白花丹醌可以上调DR5的表达。(5)Western blotting发现白花丹醌单独作用及其联合rsTRAIL应用时上调DR5、激活caspase-8和下调c-FLIP表达。结论: 白花丹醌具有增强TRAIL诱导Kasumi-1细胞凋亡的作用,其机制与DR5上调、caspase-8激活和c-FLIP下调有关。     

Morphine promotes apoptosis in Jurkat cells.

Patients with intravenous heroin addiction are prone to recurrent infections and at times these infections are fatal. We evaluated the effect of morphine on the apoptosis of Jurkat cells and freshly isolated human T lymphocytes. Morphine promoted apoptosis of both the Jurkat cells and the freshly isolated T lymphocytes in a dose-dependent manner. DAGO, a specific mu receptor agonist, also promoted Jurkat cell apoptosis. DNA isolated from morphine-treated Jurkat cells and T lymphocytes also showed integer multiples of 200 base pairs. Superoxide dismutase (SOD) enhanced lymphocyte apoptosis; whereas catalase attenuated the morphine-induced apoptosis of Jurkat cells as well as of T lymphocytes. Morphine-treated Jurkat cells also showed a decreased expression of bcl-2 and an enhanced expression of bax. In addition, morphine-treated Jurkat cells showed activation of caspase-3. These results indicate that morphine-induced T lymphocyte apoptosis may be mediated through the generation of reactive oxygen species. The change in ratio of bax and bcl-2 seems to tilt the balance toward apoptosis, leading to the activation of caspase-3. This study provides further support for the hypothesis that morphine may be directly compromising immune function by enhancing apoptosis of T lymphocytes in patients with heroin addiction.     

转染反义Fas阻断T细胞凋亡及对肿瘤的治疗意义

目的 通过阻断Ｔ细胞的Ｆａｓ信号传递途径,探讨消除肿瘤对Ｔ细胞的攻击及其对肿瘤的治疗意义。方法 流式细胞术、ＲＴ－ＰＣＲ方法检测卵巢癌细胞表达Ｆａｓ和ＦａｓＬ。构建ｐｃＤＮＡ３－反义Ｆａｓ真核表达载体,经脂质体转染Ｊｕｒｋａｔ细胞,流式细胞仪检测Ｆａｓ表达变化。以Ａｎｎｅｘｉｎ－Ｖ和ＭＴＴ法检测转染反义Ｆａｓ基因对Ｊｕｒｋａｔ细胞凋亡的影响。采用ＭＴＴ体外杀伤实验观察３ＡＯ对Ｊｕｒｋａｔ细胞杀伤变化。结果 ６种卵巢癌细胞均表达Ｆａｓ和ＦａｓＬ。ｐｃＤＮＡ３－反义Ｆａｓ基因可以使Ｊｕｒｋａｔ细胞表达Ｆａｓ量下降并部分阻断Ｆａｓ单抗诱导的Ｊｕｒｋａｔ细胞凋亡,３ＡＯ对其杀伤减弱。结论 卵巢癌细胞表达ＦａｓＬ可能是其逃逸免疫监视并产生对淋巴细胞攻击的原因之一;应用反义技术阻断Ｆａｓ表达,可部分阻断Ｆａｓ单抗诱导Ｊｕｒ     

Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes

The mechanisms by which beta1 integrins modulate T cell functions are still poorly defined. We have previously reported that signaling via the collagen type I (Coll I) receptor, alpha2beta1 integrin, inhibited FasL expression and protected Jurkat T cells from activation-induced cell death (AICD). In this study, we examined whether Coll I signaling in T cells also modulates the expression of the human receptor activator of nuclear factor-kappaB ligand (RANKL), a recently identified TNF family member which has important functions in osteoclastogenesis, cell survival and apoptosis. Our results show that in both Jurkat T cells and human primary T cells, Coll I signaling significantly reduces activation-induced RANKL expression by 50-60%. We also found that RANKL is not involved in AICD but participates in doxorubicin-induced apoptosis of leukemia T cell lines including Jurkat, CEM and HSB-2. In this respect, Coll I protected leukemia T cell lines from doxorubicin-induced apoptosis by inhibiting doxorubicin-induced RANKL expression. Together, our results suggest that by limiting the production of RANKL, Coll I signaling may contribute to the resistance of leukemia T cells to chemotherapy. Our study also emphasizes the importance Coll I signaling may have in the control of RANKL-associated T cell functions.     

Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells

To elucidate if the Fas/FasL signal pathway participates in the immune escape of tumor cells, and if contemporary Fas/FasL and tumor necrosis factor (TNF))-induced apoptosis is better for immune cell survival than just blocking Fas/FasL-induced apoptotic signal. FasL expression in mouse H22 hepatocellular cancer cells was suppressed by the siRNA technique. The wild-type Ad5 14.7K gene was amplified by polymerase chain reaction and transduced into Jurkat T-cells. Apoptosis of target Jurkat cells was detected by flow cytometry. TNF-alpha in the culture supernatant of H22 cells by ELISA was seen. FasL and 14.7K gene expression in stably transfected or transduced clones were determined by Western blotting. As a result, FasL expression in H22 cells was down-regulated after stable transfection with a plasmid encoding antisense FasL cDNA. Down-regulation of FasL expression in H22 cells had no effect on tumor growth in vitro. There was an apparent decrease in the number of apoptotic Jurkat T-cells after coculture with transfected H22 cells, relative to coculture with FasL-expressing untransfected cells. Compared with untransduced Jurkat cells, apoptotic rates in 14.7K-transduced Jurkat cells were significantly reduced in three different E/T ratios (P < 0.01), respectively. We conclude that Fas/FasL signal pathway participates in the immune escape of tumor cells by inducing immune cells apoptosis. Reducing the expression of FasL in tumor cells can decrease the apoptotic rate of immune cells, further blocking the apoptotic signal pathway of immune cells by preventing TNF-induced apoptosis can increase the survival of immune cells.     

Butyric acid-induced apoptosis of murine thymocytes, splenic T cells, and human Jurkat T cells.

The purpose of this study was to examine the effect of butyric acid, an extracellular metabolite from periodontopathic bacteria, on apoptosis induction in murine thymocytes, splenic T cells, and human Jurkat T cells. Butyric acid significantly suppressed T-cell viability in both a concentration- and time-dependent fashion. The results of DNA fragmentation assay indicated that butyric acid rapidly induced apoptosis in thymocytes (with 1.25 mM butyric acid and 6 h after treatment) and in splenic T cells and Jurkat cells (with 2.5 mM butyric acid and 16 h after treatment). Incubation of thymocytes or Jurkat cells with 5 mM butyric acid for 21 h resulted in the typical ladder pattern of DNA fragmentation. Furthermore, Jurkat cells treated with 5 mM butyric acid showed the characteristic pattern of apoptotic cells such as chromatin condensation and hypodiploid nuclei. Experiments with fractionated subpopulations of splenic T cells revealed that DNA fragmentation was predominantly observed in CD4+ T cells. Butyric acid-induced apoptosis of thymocytes was decreased by the protein kinase inhibitors H7 and staurosporine. These inhibitors were less effective with similarly treated splenic T cells and Jurkat cells. These data suggest that butyric acid, one of the volatile fatty acids produced by periodontopathic bacteria and one that easily penetrates the oral mucosa, can modulate the immunoregulatory cell population in periodontal tissue by inducing T-cell death through apoptosis.     

Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD)

Interleukin (IL)-2 immunotherapy is used for the treatment of metastatic melanoma and renal cell carcinoma and mediates its effects through the clonal expansion of lymphocytes. Although IL-2 remains the most effective form of therapy for these cancers, response rates are poor and dose escalation is hampered by side effects, which include vascular leak and lymphopenia. The mechanism underlying T cell loss is currently unidentified but could be the induction of activation-induced cell death (AICD) mediated by FasL. Our previous studies have shown that the amino acid taurine can attenuate apoptosis induced by a number of factors in different cell types. Here, we induced T cell AICD via CD3 and IL-2 stimulation and investigated the effect of taurine on lymphocyte apoptosis. Anti-CD3-activated Jurkat T cells treated with IL-2 significantly increased FasL expression, which was associated with increased apoptosis. Treatment with taurine prior to stimulation down-regulated FasL protein expression and partially inhibited apoptosis. Inhibition of FasL-signalling resulted in an identical reduction in apoptosis. As the kinetics of AICD are completely different in circulating T cells, we repeated these experiments in such cells to confirm our finding. Stimulation of CD4(+) circulating T cells induced apoptosis in sensitized, but not freshly isolated T cells, which was abrogated partially by taurine. In Jurkat cells it was determined that taurine-mediated down-regulation of FasL protein expression was associated with decreased FasL mRNA expression and reduced NFkappaB activation. These results reveal one possible mechanism underlying the lymphopenia observed with IL-2 immunotherapy, involving increased FasL expression leading to apoptosis. Taurine may be of use in reversing the lymphopenia associated with IL-2, thereby augmenting its immunotherapeutic potential.     

肝癌细胞系HEpG2表达FasL杀伤T淋巴细胞

为研究肝肿瘤细胞系表达FasL逃逸免疫监视的可能 ,采用逆转录 PCR方法和免疫组化法测肝癌细胞株FasL的表达 ,并测T淋巴细胞的凋亡。结果发现HEpG2细胞在mRNA水平和蛋白质水平上皆可检测到FasL的高表达 ,而 772 1细胞未能测到。HEpG2细胞与JurkatT淋巴细胞共培养后 ,19 4%的T细胞发生凋亡 ,抗FasL的单抗能阻断这种凋亡。因而肝肿瘤细胞HEpG2表达功能性的FasL ,能杀伤Fas阳性[1] 的T淋巴细胞。